Several reports indicate that chemo-resistant cancer cells become highly adapted to intrinsic oxidative stress by up-regulating their antioxidant systems, which causes an increase of intracellular GSH content. Doxorubicin is one of the most widely used drugs for tumor treatment, able to kill cancer cells through several mechanisms. However, doxorubicin use is limited by its toxicity and cancer resistance. Therefore, new therapeutic strategies able to reduce doses and to overcome chemo-resistance are needed. A new class of glutathione-responsive cyclodextrin nanosponges (GSH-NS), is able to release anticancer drugs preferentially in cells having high GSH content. Doxorubicin-loaded GSH-NS, in the cancer cells with high GSH content, inhibited clonogenic growth, cell viability, topoisomerase II activity and induced DNA damage with higher effectiveness than free drug. Moreover, GSH-NS reduced the development of human tumor in xenograft models more than free drug. These characteristics indicate that GSH-NS can be a suitable drug delivery carrier for future applications in cancer therapy.

GSH-targeted nanosponges increase doxorubicin-induced toxicity "in vitro" and "in vivo" in cancer cells with high antioxidant defenses

DAGA, MARTINA;ULLIO, CHIARA;ARGENZIANO, MONICA;DIANZANI, Chiara;CAVALLI, Roberta;TROTTA, Francesco;FERRETTI, Carlo;ZARA, Gian Paolo;CIAMPORCERO, ERIC STEFANO;PETTAZZONI, PIERGIORGIO;PIZZIMENTI, Stefania
;
BARRERA, Giuseppina
Last
2016

Abstract

Several reports indicate that chemo-resistant cancer cells become highly adapted to intrinsic oxidative stress by up-regulating their antioxidant systems, which causes an increase of intracellular GSH content. Doxorubicin is one of the most widely used drugs for tumor treatment, able to kill cancer cells through several mechanisms. However, doxorubicin use is limited by its toxicity and cancer resistance. Therefore, new therapeutic strategies able to reduce doses and to overcome chemo-resistance are needed. A new class of glutathione-responsive cyclodextrin nanosponges (GSH-NS), is able to release anticancer drugs preferentially in cells having high GSH content. Doxorubicin-loaded GSH-NS, in the cancer cells with high GSH content, inhibited clonogenic growth, cell viability, topoisomerase II activity and induced DNA damage with higher effectiveness than free drug. Moreover, GSH-NS reduced the development of human tumor in xenograft models more than free drug. These characteristics indicate that GSH-NS can be a suitable drug delivery carrier for future applications in cancer therapy.
97
24
37
www.elsevier.com/locate/freeradbiomed
Doxorubicin; GSH-targeted nanosponges; Prostate and colon cancer cells; Toxic effects; Biochemistry; Physiology (medical)
Daga, Martina; Ullio, Chiara; Argenziano, Monica; Dianzani, Chiara; Cavalli, Roberta; Trotta, Francesco; Ferretti, Carlo; Zara, Gian Paolo; Gigliotti, Casimiro L.; Ciamporcero, Eric S.; Pettazzoni, Piergiorgio; Corti, Denise; Pizzimenti, Stefania; Barrera, Giuseppina
File in questo prodotto:
File Dimensione Formato  
2016 FRBM GSH-NS.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 2.53 MB
Formato Adobe PDF
2.53 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
2016 FREE RAD BIOL MED GSH-NS_POST PRINT_4aperto.pdf

Accesso aperto con embargo fino al 14/05/2017

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 763.66 kB
Formato Adobe PDF
763.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1572903
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 51
social impact